0001415889-24-003485.txt : 20240213 0001415889-24-003485.hdr.sgml : 20240213 20240213092355 ACCESSION NUMBER: 0001415889-24-003485 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240211 FILED AS OF DATE: 20240213 DATE AS OF CHANGE: 20240213 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Palleiko Benjamin L CENTRAL INDEX KEY: 0001366244 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 24622910 MAIL ADDRESS: STREET 1: C/O KALVISTA PHARMACEUTICALS, INC. STREET 2: ONE KENDALL SQUARE, BLD 200, STE 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 FORMER NAME: FORMER CONFORMED NAME: Palleiko Ben DATE OF NAME CHANGE: 20060615 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4 1 form4-02132024_020249.xml X0508 4 2024-02-11 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001366244 Palleiko Benjamin L C/O KALVISTA PHARMACEUTICALS, INC. 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 false true false false CFO, CBO 0 Common Stock 2024-02-11 4 A 0 87500 A 199943 D Performance Stock Units 2024-02-11 4 A 0 83333 0 A Common Stock 83333 83333 D Shares earned upon the vesting of a percentage of the performance stock units ("PSUs") granted to the Reporting Person on March 11, 2022. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of performance data metric goals ("Performance Metrics"). 100% of the total number of shares subject to the PSUs vested on February 11, 2024, upon Performance Metrics achieved. Each PSU represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. Shares earned upon the vesting of a percentage of the PSUs granted to the Reporting Person on January 10, 2024. Each PSU represents a contingent right to receive one share of Issuer common stock upon the Issuer's achievement of Performance Metrics. 1/4th of the total number of shares subject to the PSU shall vest on each quarterly anniversary of the Vesting Commencement Date of February 17, 2024, upon Performance Metrics achieved, subject to continued service through each vesting date. /s/ Benjamin L. Palleiko 2024-02-13